These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9487561)

  • 1. Tissue disposition of zidovudine and its phosphorylated metabolites in zidovudine-treated healthy and retrovirus infected mice.
    Chow HH; Brookshier G; Li P
    Pharm Res; 1998 Jan; 15(1):139-44. PubMed ID: 9487561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo tissue disposition of 3'-azido-3'-deoxythymidine and its anabolites in control and retrovirus-infected mice.
    Chow HH; Li P; Brookshier G; Tang Y
    Drug Metab Dispos; 1997 Apr; 25(4):412-22. PubMed ID: 9107539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal encapsulation of 3'-azido-3'-deoxythymidine (AZT) results in decreased bone marrow toxicity and enhanced activity against murine AIDS-induced immunosuppression.
    Phillips NC; Skamene E; Tsoukas C
    J Acquir Immune Defic Syndr (1988); 1991; 4(10):959-66. PubMed ID: 1890605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracellular pharmacokinetic study of zidovudine and its phosphorylated metabolites.
    Mu L; Zhou R; Tang F; Liu X; Li S; Xie F; Xie X; Peng J; Yu P
    Acta Pharm Sin B; 2016 Mar; 6(2):158-62. PubMed ID: 27006900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transplacental pharmacokinetics and fetal distribution of azidothymidine, its glucuronide, and phosphorylated metabolites in late-term rhesus macaques after maternal infusion.
    Patterson TA; Binienda ZK; Lipe GW; Gillam MP; Slikker W; Sandberg JA
    Drug Metab Dispos; 1997 Apr; 25(4):453-9. PubMed ID: 9107545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zidovudine (AZT) reduces virus titer, retards immune dysfunction, and prolongs survival in the LP-BM5 murine induced immunodeficiency model.
    Basham T; Rios CD; Holdener T; Merigan TC
    J Infect Dis; 1990 May; 161(5):1006-9. PubMed ID: 2157768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ultrasensitive method to quantify intracellular zidovudine mono-, di- and triphosphate concentrations in peripheral blood mononuclear cells by liquid chromatography-tandem mass spectrometry.
    Kinai E; Gatanaga H; Kikuchi Y; Oka S; Kato S
    J Mass Spectrom; 2015 Jun; 50(6):783-91. PubMed ID: 26169132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of bis(t-butyl-SATE)-AZTMP, a bispivaloylthioethyl prodrug for intracellular delivery of zidovudine monophosphate, in mice.
    Tan X; Boudinot FD; Chu CK; Egron D; Perigaud C; Gosselin G; Imbach JL
    Antivir Chem Chemother; 2000 May; 11(3):203-11. PubMed ID: 10901291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of dosing schedule upon suppression of a retrovirus in a murine model of AIDS encephalopathy.
    Bilello JA; Eiseman JL; Standiford HC; Drusano GL
    Antimicrob Agents Chemother; 1994 Mar; 38(3):628-31. PubMed ID: 8203866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of murine AIDS by combination of AZT and dideoxycytidine 5'-triphosphate.
    Fraternale A; Casabianca A; Rossi L; Chiarantini L; Brandi G; Aluigi G; Schiavano GF; Magnani M
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jun; 12(2):164-73. PubMed ID: 8680888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of murine AIDS by alternate administration of azidothymidine and fludarabine monophosphate.
    Fraternale A; Casabianca A; Tonelli A; Vallanti G; Chiarantini L; Brandi G; Celeste AG; Magnani M
    J Acquir Immune Defic Syndr; 2000 Mar; 23(3):209-20. PubMed ID: 10839656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of rates of intracellular metabolism of zidovudine in human and primate peripheral blood mononuclear cells.
    Qian M; Chandrasena G; Ho RJ; Unadkat JD
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2398-403. PubMed ID: 7840577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites.
    Barry MG; Khoo SH; Veal GJ; Hoggard PG; Gibbons SE; Wilkins EG; Williams O; Breckenridge AM; Back DJ
    AIDS; 1996 Oct; 10(12):1361-7. PubMed ID: 8902065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time-dependent changes induced by azidothymidine in erythroid progenitor colonies in immunodeficient mice.
    Chow FP; Hamburger AW
    Exp Hematol; 1992 Feb; 20(2):245-50. PubMed ID: 1544395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of zidovudine on Friend virus complex infection in Rfv-3r/s genotype-containing mice used as a model for HIV infection.
    Morrey JD; Warren RP; Okleberry KM; Burger RA; Johnston MI; Sidwell RW
    J Acquir Immune Defic Syndr (1988); 1990; 3(5):500-10. PubMed ID: 2157836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of 3'azidothymidine administered in drinking water or by continuous infusion on the development of MAIDS.
    Eiseman JL; Yetter RA; Fredrickson TN; Shapiro SG; MacAuley C; Bilello JA
    Antiviral Res; 1991 Dec; 16(4):307-26. PubMed ID: 1663732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue distribution and metabolic disposition of zidovudine in rats.
    de Miranda P; Burnette TC; Good SS
    Drug Metab Dispos; 1990; 18(3):315-20. PubMed ID: 1974192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma drug levels compared with DNA incorporation of 3'-azido-3'-deoxythymidine (AZT) in adult cynomolgus (Macaca fascicularis) monkeys.
    Olivero OA; Reddy MK; Pietras SM; Poirier MC
    Exp Biol Med (Maywood); 2001 May; 226(5):446-9. PubMed ID: 11393173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermittent, alternating, and concurrent regimens of zidovudine and 2'-3' dideoxycytidine in the LP-BM5 murine induced immunodeficiency model.
    Basham T; Holdener T; Merigan T
    J Infect Dis; 1991 Apr; 163(4):869-72. PubMed ID: 1849164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.